Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NEOG vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: NEOG 1 – 5 VCYT Matrix Metrics: NEOG 3 – 7 VCYT

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NEOG carries a Unified Composite Score of 43.0/100 (HOLD) at $10.88 (36.3x Forward P/E, -0.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).

  • Technical & Structure Timing Caution: NEOG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.3); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NEOG vs VCYT
NEOG NASDAQ
Neogen Corp
In Vitro & In Vivo Diagnostic Substances
$10.88
-3.12% 1D
Market Cap $2.5B
TTM Revenue $884M
Forward P/E 36.3x
Beta / 30D Vol 1.41β · 40% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 23.0 Fund 46.0 Flow 61.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 36.3 · SMA20: $11.85 · SMA50: $12.22
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79

6-Pillar Scorecard Institutional Category Breakdown (NEOG 1 – 5 VCYT)

Columns: Metric · NEOG · VCYT
1. Valuation Multiples VCYT
Forward P/E 36.3x 15.3x
Trailing P/E 16.0x 15.8x
PEG Ratio 0.66x N/M
EV / Revenue 3.5x 3.1x
2. Growth & Scale VCYT
Revenue Growth (YoY) +6.5% +15.1%
Earnings Growth (YoY) -85.6% +58.3%
TTM Revenue (USD) $884M $582M
Market Cap $2.5B $2.0B
3. Profitability & Quality VCYT
Gross Margin 47.4% 74.2%
Operating Margin -0.8% 15.0%
Net Profit Margin -6.3% 21.8%
Return on Equity (ROE) -2.7% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $50M $162M
Cash Flow Margin 5.6% 27.8%
Net Cash / Leverage $602M Net Debt (0.37x D/E) $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NEOG
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 46.0% (25th %ile) 197.3% (47th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 48.2% of Rev ($426M) 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NEOG (3) vs VCYT (7)
Institutional Metric NEOG VCYT Criterion Row Edge
Market Capitalization
Scale
$2.5B $2.0B Larger Scale NEOG
Trailing P/E Ratio
Valuation
16.0x 15.8x Lower Multiple VCYT
Forward P/E Ratio
Valuation
36.3x 15.3x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+6.5% +15.1% Higher Growth VCYT
Operating Margin (TTM)
Profitability
-0.8% 15.0% Higher Margin VCYT
Net Profit Margin
Profitability
-6.3% 21.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
-2.7% 9.4% Higher ROE VCYT
52-Week Range Position
Momentum
62% ($5–$14) 5% ($22–$61) Stronger Trend NEOG
Beta / 30D Volatility
Risk Regime
1.41β · 40% Vol 3.01β · 199% Vol Lower Realized Risk NEOG
Unified Institutional Score
Composite Signal
43.0 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$884M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.4% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.66x PEG · 3.5x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$50M ($602M Net Debt (0.37x D/E)) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NEOG +36.45 pp
NEOG: -7.87% · VCYT: -44.32%
3M Horizon NEOG +35.02 pp
NEOG: -5.96% · VCYT: -40.98%
6M Horizon NEOG +69.24 pp
NEOG: +27.1% · VCYT: -42.14%
1Y Horizon NEOG +110.58 pp
NEOG: +70.8% · VCYT: -39.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NEOG Revenue VCYT Revenue NEOG Op. Margin VCYT Op. Margin Margin Leader
FY2019 $410M $120M 16.4% -12.6% NEOG
FY2020 $420M $120M 16.1% -30.1% NEOG
FY2021 $470M $220M 15.8% -37.3% NEOG
FY2022 $530M $300M 11.1% -13.9% NEOG
FY2023 $820M $360M 4.6% -23.8% NEOG
FY2024 $920M $450M 6.3% 3.6% NEOG
FY2025 $890M $520M -118.6% 11.2% VCYT
FY2026 $870M N/A -2.5% N/A NEOG

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NEOG CONSOLIDATION
39d in phase · OBV NEUTRAL
Current IV 46.0%
IV Percentile 25th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact NEOG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NEOG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.5B market capitalization and -0.8% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($426M)
90D Engineering Disclosures 0 Published
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ NEOG vs VCYT Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NEOG carries a Unified Composite Score of 43.0/100 (HOLD) at $10.88 (36.3x Forward P/E, -0.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: NEOG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.3); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: NEOG posts +6.5% YoY revenue growth and -85.6% YoY earnings growth on $884M TTM revenue (47.4% gross margin, -0.8% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), NEOG cumulative revenue shifted +112.2% while VCYT shifted +333.3%. In operating R&D and SG&A reinvestment, NEOG deploys 48.2% of Rev ($426M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

VCYT screens cheaper on headline valuation multiples. NEOG trades at 36.3x Forward P/E, 16.0x Trailing P/E, 0.66x PEG, and 3.5x EV/Revenue (5.6% FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEOG (-2.7% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NEOG carries 46.0% implied volatility (25th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 40% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.